Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines in oncology, autoimmune disease and inflammatory conditions. The NRIX news feed on Stock Titan aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how its pipeline and collaborations evolve over time.
News about Nurix frequently centers on clinical trial results and milestones for its lead programs. Recent releases describe new and updated data from Phase 1a/1b studies of the BTK degrader bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, including objective response rates, durability of responses and safety findings. Additional updates cover translational and clinical data for NX-1607, an oral CBL-B inhibitor for solid tumors, highlighting immune activation, tumor microenvironment remodeling and disease control in heavily pretreated patients.
Investors and clinicians can also use the NRIX news page to track corporate and regulatory events such as the initiation of the pivotal DAYBreak CLL-201 Phase 2 study, plans for a confirmatory Phase 3 trial, expansion of bexobrutideg into autoimmune and inflammatory indications, and participation in major medical and investor conferences including the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer (SITC) and the J.P. Morgan Healthcare Conference.
Nurix’s news flow further includes announcements on strategic collaborations and governance, such as progress in partnered STAT6 and IRAK4 degrader programs with Sanofi and Gilead, and board appointments that add drug development and commercialization experience. Bookmark this page to access a consolidated view of NRIX press releases and related coverage as the company advances its targeted protein degradation pipeline.
Nurix Therapeutics (NRIX) reported promising results from its Phase 1 trial of NX-2127, a treatment for chronic lymphocytic leukemia (CLL) at the ASH Annual Meeting. The trial included 36 adults, with 23 being heavily pretreated CLL patients. NX-2127 demonstrated a 33% overall response rate and effective BTK degradation, regardless of previous treatments or BTK mutations. The safety profile was consistent with existing BTK therapies. The company continues to explore NX-2127's potential while preparing for further clinical updates in 2023.
Nurix Therapeutics (Nasdaq: NRIX) has announced a live webcast on December 12, 2022, at 8:30 PM CT to review clinical data from the Phase 1 trial of its BTK degrader program, NX-2127. The event will feature insights from Dr. Anthony Mato, focusing on chronic lymphocytic leukemia patients. NX-2127 targets Bruton’s tyrosine kinase and is currently being evaluated in patients with relapsed or refractory B-cell malignancies. The ongoing study is registered under NCT04830137.
Nurix Therapeutics presented promising preclinical data for its CBL-B inhibitor NX-0255 at the 37th Annual Meeting of the SITC. This data suggests that NX-0255 can enhance T-cell therapy in the DeTIL-0255 program aimed at treating gynecologic malignancies. The ongoing Phase 1 trial has completed its safety run-in with positive outcomes in patients. Furthermore, FDA feedback supports the combination of NX-0255 with DeTIL-0255, indicating potential for future trial expansions. Nurix plans to advance the development of its CBL-B inhibitors in 2023.
Nurix Therapeutics (NRIX) presented initial biomarker data from its Phase 1 trial of NX-1607, an innovative CBL-B inhibitor, at the SITC Annual Meeting. The results show target engagement correlating to significant anti-tumor activity, with biomarker levels indicating dose-dependency. NX-1607 effectively activates T and NK cells, enhancing immune response in tumor settings. Preliminary findings suggest a mean half-life of 6 to 8 hours for NX-1607, reinforcing its potential as a key oncology therapy. Additional updates are anticipated in 2023.
Nurix Therapeutics (NASDAQ: NRIX) announced a clinical update for its ongoing Phase 1 trial of NX-2127, a targeted protein degrader for patients with hematologic malignancies. The updates will be presented at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. Dr. Anthony Mato of Memorial Sloan Kettering Cancer Center will give an oral presentation on chronic lymphocytic leukemia (CLL) patients. NX-2127 degrades Bruton’s tyrosine kinase (BTK) and is currently under evaluation in clinical trials.
Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical company focused on developing targeted protein modulation therapies for cancer, announced key participation in November conferences. CEO Arthur T. Sands will present at:
- Credit Suisse 31st Annual Healthcare Conference on November 8, 11:25 - 11:55 a.m. ET.
- Piper Sandler 34th Annual Healthcare Conference on November 30, 4:30 - 4:55 p.m. ET.
The events will be webcast and available on the company's website for about 30 days afterward.
Nurix Therapeutics (Nasdaq: NRIX) announced promising initial results from the NX-2127 clinical trial for patients with diffuse large B cell lymphoma (DLBCL). A patient achieved a complete response at 8 weeks, confirmed at 16 weeks, after receiving 300 mg of NX-2127 daily. This dual-action drug targets Bruton’s tyrosine kinase (BTK) and aids in degrading key proteins linked to tumor proliferation. The NX-2127 trial shows potential for addressing unmet medical needs in aggressive lymphomas, with further updates expected at the upcoming American Society of Hematology meeting in December.
Nurix Therapeutics (Nasdaq: NRIX) announced plans to present at the 5th Annual TPD Summit from October 25-28, 2022, in Boston, MA. A Keynote Plenary will be delivered by Arthur T. Sands, M.D., Ph.D., the CEO, discussing advancements in BTK degraders for hematologic malignancies. Other presentations include topics on targeted protein degradation and orally active, brain-penetrant degraders. Nurix focuses on developing therapies that modulate cellular protein levels, utilizing their DELigase discovery platform.
Nurix Therapeutics reported Q3 2022 results, highlighting a gross revenue of $10.8 million, up from $10.3 million in Q3 2021. The company raised $95 million from two registered direct offerings in July, bolstering its cash position to $413.6 million as of August 31, 2022. R&D expenses rose to $47.8 million, reflecting increased clinical activities, while net loss was $45.7 million or $0.90 per share. Nurix expanded its leadership team and announced six presentations at the SITC 2022 annual meeting, including initial data for its NX-1607 program.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced six poster presentations for the Society for Immunotherapy of Cancer’s 37th Annual Meeting from November 8-12, 2022, in Boston. The presentations highlight the company’s targeted protein modulation platform and CBL-B inhibitors, including NX-1607 and DeTIL-0255. Key data to be presented includes initial biomarker data from a Phase 1 trial of NX-1607 in patients with advanced malignancies. These advancements could enhance anti-tumor immunity and broaden treatment options for various cancer types.